Rujukan Faktor VIII (ubat)

  1. 1 2 World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (para penyunting). WHO Model Formulary 2008. World Health Organization. halaman 259–60. hdl:10665/44053. ISBN 9789241547659.
  2. 1 2 British National Formulary : BNF 69. British Medical Association. 2015. m/s. 171. ISBN 978-0857111562.
  3. ↑ "Alphanate – Summary of Product Characteristics (SPC) – (eMC)". www.medicines.org.uk. Diarkib daripada yang asal pada 9 January 2017. Dicapai pada 8 January 2017.
  4. ↑ Potts, D.M. (2011). Queen Victoria's Gene: Haemophilia and the Royal Family (Chapter 5) (dalam bahasa Inggeris). The History Press. ISBN 978-0752471969. Diarkib daripada yang asal pada 2017-01-09.
  5. ↑ Sibinga, Cees Smit; Das, P.C.; Overby, L.R. (2012). Biotechnology in blood transfusion: Proceedings of the Twelfth Annual Symposium on Blood Transfusion, Groningen 1987, organized by the Red Cross Blood Bank Groningen-Drenthe (dalam bahasa Inggeris). Springer Science & Business Media. m/s. 224. ISBN 978-1461317616. Diarkib daripada yang asal pada 2017-01-09.
  6. ↑ Buckel, P. (2012). Recombinant Protein Drugs (dalam bahasa Inggeris). Birkhäuser. m/s. 79. ISBN 978-3034883467. Diarkib daripada yang asal pada 2017-01-09.
  7. ↑ Hillyer, Christopher D. (2006). Blood Banking and Transfusion Medicine: Basic Principles & Practice (dalam bahasa Inggeris). Elsevier Health Sciences. m/s. 353. ISBN 0443069816. Diarkib daripada yang asal pada 2017-01-09.
  8. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  9. 1 2 Nathwani, Amit C.; Davidoff, Andrew M.; Tuddenham, Edward G. D. (October 2017). "Gene Therapy for Hemophilia". Hematology/Oncology Clinics of North America. 31 (5): 853–868. doi:10.1016/j.hoc.2017.06.011. ISSN 1558-1977. PMID 28895852.
  10. ↑ Machin, Nicoletta; Ragni, Margaret V.; Smith, Kenneth J. (2018-07-24). "Gene therapy in hemophilia A: a cost-effectiveness analysis". Blood Advances. 2 (14): 1792–1798. doi:10.1182/bloodadvances.2018021345. ISSN 2473-9529. PMC 6058236. PMID 30042145.